| Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. GM Bores, FP Huger, W Petko, AE Mutlib, F Camacho, DK Rush, DE Selk, ... Journal of Pharmacology and Experimental Therapeutics 277 (2), 728-738, 1996 | 364 | 1996 |
| Torcetrapib‐induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone MJ Forrest, D Bloomfield, RJ Briscoe, PN Brown, AM Cumiskey, J Ehrhart, ... British journal of pharmacology 154 (7), 1465-1473, 2008 | 330 | 2008 |
| Discovery of potent 3, 5-diphenyl-1, 2, 4-oxadiazole sphingosine-1-phosphate-1 (S1P1) receptor agonists with exceptional selectivity against S1P2 and S1P3 Z Li, W Chen, JJ Hale, CL Lynch, SG Mills, R Hajdu, CA Keohane, ... Journal of medicinal chemistry 48 (20), 6169-6173, 2005 | 154 | 2005 |
| Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative JP Piccini, DJ Whellan, BR Berridge, JK Finkle, SD Pettit, N Stockbridge, ... American heart journal 158 (3), 317-326, 2009 | 141 | 2009 |
| Design, Synthesis, and Evaluation of a Novel 4-Aminomethyl-4-fluoropiperidine as a T-Type Ca2+ Channel Antagonist WD Shipe, JC Barrow, ZQ Yang, CW Lindsley, FV Yang, KAS Schlegel, ... Journal of medicinal chemistry 51 (13), 3692-3695, 2008 | 140 | 2008 |
| Comparison of the inhibitory potencies of N (G)-methyl-, N (G)-nitro-and N (G)-amino-L-arginine on EDRF function in the rat: evidence for continuous basal EDRF release. HM Vargas, JM Cuevas, LJ Ignarro, G Chaudhuri Journal of Pharmacology and Experimental Therapeutics 257 (3), 1208-1215, 1991 | 112 | 1991 |
| Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics HM Vargas, AS Bass, A Breidenbach, HS Feldman, GA Gintant, ... Journal of pharmacological and toxicological methods 58 (2), 72-76, 2008 | 104 | 2008 |
| Phenyl-substituted analogs of oxotremorine as muscarinic antagonists BM Nilsson, HM Vargas, B Ringdahl, U Hacksell Journal of medicinal chemistry 35 (2), 285-294, 1992 | 104 | 1992 |
| Discovery of 1, 4-substituted piperidines as potent and selective inhibitors of T-type calcium channels ZQ Yang, JC Barrow, WD Shipe, KAS Schlegel, Y Shu, FV Yang, ... Journal of medicinal chemistry 51 (20), 6471-6477, 2008 | 98 | 2008 |
| Vascular alpha-1 adrenergic receptor subtypes in the regulation of arterial pressure HM Vargas, AJ Gorman Life sciences 57 (25), 2291-2308, 1995 | 92 | 1995 |
| Proarrhythmia risk assessment in human induced pluripotent stem cell-derived cardiomyocytes using the maestro MEA platform Y Qu, HM Vargas Toxicological Sciences 147 (1), 286-295, 2015 | 88 | 2015 |
| Physiological release of nitric oxide is dependent on the level of vascular tone HM Vargas, LJ Ignarro, G Chaudhuri European journal of pharmacology 190 (3), 393-397, 1990 | 76 | 1990 |
| The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative L Ewart, M Aylott, M Deurinck, M Engwall, DJ Gallacher, H Geys, P Jarvis, ... Toxicological Sciences 142 (2), 427-435, 2014 | 74 | 2014 |
| Safety pharmacology investigations on the nervous system: An industry survey S Authier, J Arezzo, MS Delatte, MJ Kallman, C Markgraf, D Paquette, ... Journal of pharmacological and toxicological methods 81, 37-46, 2016 | 69 | 2016 |
| Discovery of AMG 369, a Thiazolo[5,4-b]pyridine Agonist of S1P1 and S1P5 VJ Cee, M Frohn, BA Lanman, J Golden, K Muller, S Neira, A Pickrell, ... ACS Medicinal Chemistry Letters 2 (2), 107-112, 2011 | 64 | 2011 |
| Time for a fully integrated nonclinical–clinical risk assessment to streamline QT prolongation liability determinations: A pharma industry perspective HM Vargas, MG Rolf, TA Wisialowski, W Achanzar, A Bahinski, A Bass, ... Clinical Pharmacology & Therapeutics 109 (2), 310-318, 2021 | 59 | 2021 |
| Assessing the predictive value of the rodent neurofunctional assessment for commonly reported adverse events in phase I clinical trials AN Mead, HR Amouzadeh, K Chapman, L Ewart, A Giarola, SJ Jackson, ... Regulatory Toxicology and Pharmacology 80, 348-357, 2016 | 58 | 2016 |
| Vascular α1D-adrenoceptors have a role in the pressor response to phenylephrine in the pithed rat L Zhou, HM Vargas European journal of pharmacology 305 (1-3), 173-176, 1996 | 55 | 1996 |
| Assessment of two external telemetry systems (PhysioJacket™ and JET™) in beagle dogs with telemetry implants RW Chui, A Fosdick, J Jiang, BA Bruenner, HM Vargas Journal of Pharmacological and Toxicological Methods 60 (1), 58-68, 2009 | 54 | 2009 |
| Evaluation of drug‐induced QT interval prolongation in animal and human studies: a literature review of concordance HM Vargas, AS Bass, J Koerner, S Matis‐Mitchell, MK Pugsley, M Skinner, ... British journal of pharmacology 172 (16), 4002-4011, 2015 | 52 | 2015 |
D J LeishmanVice President, Translational and Quantitative Toxicology (TQT)在 safetypharmacologysource.com 的电子邮件经过验证
